Remifemin
This article was originally published in The Tan Sheet
Executive Summary
GSK did not provide International Menopause Society with unrestricted educational grant to create Powering Informed Choices Initiative, which promotes firm's Remifemin, as stated in 1"The Tan Sheet" Oct. 29, p. 13...
You may also be interested in...
Menopause Herbals Viewed Warily By Patients & Doctors, Surveys Show
Soy, vitamin E and black cohosh are the dietary supplement ingredients that doctors feel most comfortable recommending to their patients for menopause, according to a recent Southern California University of Health Sciences survey.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.